Best SARMs Buying Complete Guide

 

Best SARMs Buying Complete Guide

Let’s discuss what SARMs can do for you, and what you should know when it concerns buying and using SARMS.

Are SARMs Legal?

Recreational SARMs within dietary supplements exist in somewhat grey areas: they’re sold in dietary supplements, and they’re also a DEA-controlled substance — in the same category as steroids

Athletes seeking to compete professionally should know The World Anti-Doping Agency (WADA) prohibits SARMs

Are SARMs Safe?

Using SARMs recreationally for bodybuilding is not an FDA-approved usage, meaning safety is not guaranteed. Research is limited as to how they affect the body long-term, and there are no scientific investigations into using them in cycles recreationally

Dietary supplements that aren’t FDA-approved are not regulated, including products purporting to contain SARMs. The ingredient list could be misleading, stating inaccurate or nonexistent quantities of the SARM in question

Can SARMs Make You Stronger?

Yes, certain SARMs can improve your strength, particularly when combined with intensive workouts. Plenty of studies confirm that SARMs increase participants’ physical function (which includes strength). 

Where Can You Find SARMs for Sale?

Various dietary supplements targeted at bodybuilders and fitness enthusiasts claim to include SARMs. You should take these labels with a grain of salt, especially if the brand isn’t reputable. 

Look for highly-reviewed vendors that are well-known. It isn’t wise to purchase SARMs from private individuals or dodgy places, no matter what strength or quantity they advertise.

How and When Should You Use SARMs?

You should only use SARMs if you’re otherwise healthy with no pre-existing conditions. Women should avoid trying to build muscle mass with these compounds while breastfeeding or pregnant.

SARMs are usually taken in cycles of two to three months at doses of five to 15 milligrams per day. They’re also available as pills or capsules. Personal factors like your goals (e.g., bulking vs cutting) will also play a role in how you take them.

The ideal cycle and dosage per day will depend upon the compound you’re taking: 8 weeks is pretty standard. Some bodybuilders shorten the cycle to 4 weeks or extend it to a 12-week cycle. 

As a rule, you should begin your first cycle with a low dosage to see how you react and stick to a shorter cycle of 4 to 8 weeks. For example, Testolone is highly potent even in small doses, so you don’t want to go overboard with how much you take.

You should never push your cycle to beyond 12 weeks. Avoid upping your dosage per day in large increments: if you decide to increase it, opt for no more than 5mg. 

If you experience serious side effects, cut your cycle short, and check with your doctor. SARMs may not be as dangerous as regular steroids, but that doesn’t make them 100-percent safe.

Should You Use SARMs for Bodybuilding?

There are plenty of success stories from bodybuilders using SARMs in cycles to increase muscle mass and performance. It’s up to you to weigh out the risks and benefits of taking these compounds. 

SARMs do have far fewer nasty side effects than traditional bodybuilding supplements. Still, you should exercise caution and monitor yourself carefully when you cycle.

What Are the Benefits of Taking SARMs?

SARMs offer many of the same perks as traditional steroids and testosterone supplements. They can improve muscle mass, strength, performance, and even brain function. Some can aid in cutting fat and increasing bone density.

Although these compounds are not devoid of side effects, many of the dreaded symptoms bodybuilders fear from anabolic steroids, and testosterone supplements won’t follow. 

Anabolic steroids can also cause opposite-sex characteristics to manifest, e.g. body hair growth in women or breasts in men. Both genders also experience increased cancer risk, aggression, acne, hair loss, and more.

What Are the Side Effects of SARMs?

Side effects differ depending on the type of SARM, your cycle, dosage, and overall health. Most studies exploring SARMs for medical applications illustrate minimal negative effects.

Do SARMs Lower Testosterone Levels?

Yes, a selective androgen receptor can lower testosterone levels at higher doses, depending on type of SARM. 

Should Women Take SARMs?

SARMs are an appealing alternative to anabolic steroids. Women benefit big, as the adverse consequences of traditional steroids or testosterone supplementation in women are often severe. 

Some SARMs are even considered promising in the treatment of muscle waste, breast cancer, and other disorders in women.

Is GH BOOSTER MK 677 a SARM?

GH BOOSTER MK 677, or Ibutamoren, is commonly thought to belong to the family of SARMs, but it doesn’t. It regulates growth hormone and stimulates ghrelin, the hormone responsible for hunger.

These properties make GH BOOSTER MK 677 an exciting candidate for bodybuilders looking to bulk up, but its not a SARM. 

Rounding Up 

SARMs can be excellent aids to accomplish your bodybuilding goals. Still, it’s vital to avoid abusing them and use common sense when selecting the best SARMs for you.

As with any synthetic substance, the potential for adverse effects is there. The risk is substantially lower than with other alternatives like testosterone, but it still exists. 

Remember that no official regulatory body monitors SARMs. If you choose to supplement with these products, look for manufacturers with a good reputation and reviews.

 Check out this reputable Sarms company

gh booster mk 677 15mg

WWW.SARMSAMERICA.COM 

References

  1. “Enobosarm.” National Center for Biotechnology Information. PubChem Compound Database, U.S. National Library of Medicine, pubchem.ncbi.nlm.nih.gov/compound/Enobosarm. 
  2. Pasiakos, Stefan M, et al. “Effects of Testosterone Supplementation on Body Composition and Lower-Body Muscle Function during Severe Exercise- and Diet-Induced Energy Deficit: A Proof-of-Concept, Single Centre, Randomised, Double-Blind, Controlled Trial.” EBioMedicine, Elsevier, Aug. 2019, www.ncbi.nlm.nih.gov/pmc/articles/PMC6711889/. 
  3. Davey, Rachel A, and Mathis Grossmann. “Androgen Receptor Structure, Function and Biology: From Bench to Bedside.” The Clinical Biochemist. Reviews, The Australian Association of Clinical Biochemists, Feb. 2016, www.ncbi.nlm.nih.gov/pmc/articles/PMC4810760/. 
  4. Dalton, James T, et al. “The Selective Androgen Receptor Modulator GTx-024 (Enobosarm) Improves Lean Body Mass and Physical Function in Healthy Elderly Men and Postmenopausal Women: Results of a Double-Blind, Placebo-Controlled Phase II Trial.” Journal of Cachexia, Sarcopenia and Muscle, Springer-Verlag, Sept. 2011, www.ncbi.nlm.nih.gov/pmc/articles/PMC3177038/. 
  5. Papanicolaou DA;Ather SN;Zhu H;Zhou Y;Lutkiewicz J;Scott BB;Chandler J; “A Phase IIA Randomized, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Selective Androgen Receptor Modulator (SARM), MK-0773 in Female Participants with Sarcopenia.” The Journal of Nutrition, Health & Aging, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/23732550/. 
  6. “PubMed Central Image Viewer.” National Center for Biotechnology Information, U.S. National Library of Medicine, www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click on image to zoom. 
  7. Hoffmann DB;Komrakova M;Pflug S;von Oertzen M;Saul D;Weiser L;Walde TA;Wassmann M;Schilling AF;Lehmann W;Sehmisch S; “Evaluation of Ostarine as a Selective Androgen Receptor Modulator in a Rat Model of Postmenopausal Osteoporosis.” Journal of Bone and Mineral Metabolism, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/29785666/. 
  8. Bengtsson, Victor, et al. “Narrative Review of Injuries in Powerlifting with Special Reference to Their Association to the Squat, Bench Press and Deadlift.” BMJ Open Sport & Exercise Medicine, BMJ Publishing Group, 17 July 2018, www.ncbi.nlm.nih.gov/pmc/articles/PMC6059276/. 
  9. Dobs AS;Boccia RV;Croot CC;Gabrail NY;Dalton JT;Hancock ML;Johnston MA;Steiner MS; “Effects of Enobosarm on Muscle Wasting and Physical Function in Patients with Cancer: a Double-Blind, Randomised Controlled Phase 2 Trial.” The Lancet. Oncology, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/23499390/. 
  10. “Testolone.” National Center for Biotechnology Information. PubChem Compound Database, U.S. National Library of Medicine, pubchem.ncbi.nlm.nih.gov/compound/Testolone. 
  11. Miller, Chris P, et al. “Design, Synthesis, and Preclinical Characterization of the Selective Androgen Receptor Modulator (SARM) RAD140.” ACS Medicinal Chemistry Letters, American Chemical Society, 2 Dec. 2010, www.ncbi.nlm.nih.gov/pmc/articles/PMC4018048/. 
  12. Eisenberg, Michael Louis. “Testosterone Replacement Therapy and Prostate Cancer Incidence.” The World Journal of Men’s Health, Korean Society for Sexual Medicine and Andrology, Dec. 2015, www.ncbi.nlm.nih.gov/pmc/articles/PMC4709428/. 
  13. Salerno, Monica, et al. “Anabolic Androgenic Steroids and Carcinogenicity Focusing on Leydig Cell: a Literature Review.” Oncotarget, Impact Journals LLC, 10 Apr. 2018, www.ncbi.nlm.nih.gov/pmc/articles/PMC5922407/. 
  14. Jayaraman A;Christensen A;Moser VA;Vest RS;Miller CP;Hattersley G;Pike CJ; “Selective Androgen Receptor Modulator RAD140 Is Neuroprotective in Cultured Neurons and Kainate-Lesioned Male Rats.” Endocrinology, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/24428527/. 
  15. Kaufman, Marc J, et al. “Brain and Cognition Abnormalities in Long-Term Anabolic-Androgenic Steroid Users.” Drug and Alcohol Dependence, U.S. National Library of Medicine, 1 July 2015, www.ncbi.nlm.nih.gov/pmc/articles/PMC4458166/. 
  16. Yu Z;He S;Wang D;Patel HK;Miller CP;Brown JL;Hattersley G;Saeh JC; “Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.” Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/28974548/. 
  17. “4-((R)-2-((R)-2,2,2-Trifluoro-1-Hydroxyethyl)Pyrrolidin-1-Yl)-2-(Trifluoromethyl)Benzonitrile.” National Center for Biotechnology Information. PubChem Compound Database, U.S. National Library of Medicine, pubchem.ncbi.nlm.nih.gov/compound/lgd-4033. 
  18. Basaria, Shehzad, et al. “The Safety, Pharmacokinetics, and Effects of LGD-4033, a Novel Nonsteroidal Oral, Selective Androgen Receptor Modulator, in Healthy Young Men.” The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences, Oxford University Press, Jan. 2013, www.ncbi.nlm.nih.gov/pmc/articles/PMC4111291/. 
  19. Haizlip, K M, et al. “Sex-Based Differences in Skeletal Muscle Kinetics and Fiber-Type Composition.” Physiology (Bethesda, Md.), American Physiological Society, Jan. 2015, www.ncbi.nlm.nih.gov/pmc/articles/PMC4285578/. 
  20. Miner JN;Chang W;Chapman MS;Finn PD;Hong MH;López FJ;Marschke KB;Rosen J;Schrader W;Turner R;van Oeveren A;Viveros H;Zhi L;Negro-Vilar A; “An Orally Active Selective Androgen Receptor Modulator Is Efficacious on Bone, Muscle, and Sex Function with Reduced Impact on Prostate.” Endocrinology, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/17023534/. 
  21. Alswat, Khaled A. “Gender Disparities in Osteoporosis.” Journal of Clinical Medicine Research, Elmer Press, May 2017, www.ncbi.nlm.nih.gov/pmc/articles/PMC5380170/. 
  22. Piper T;Dib J;Putz M;Fusshöller G;Pop V;Lagojda A;Kuehne D;Geyer H;Schänzer W;Thevis M; “Studies on the in Vivo Metabolism of the SARM YK11: Identification and Characterization of Metabolites Potentially Useful for Doping Controls.” Drug Testing and Analysis, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/30379415/. 
  23. Carnac, Gilles, et al. “Myostatin in the Pathophysiology of Skeletal Muscle.” Current Genomics, Bentham Science Publishers Ltd., Nov. 2007, www.ncbi.nlm.nih.gov/pmc/articles/PMC2647158/. 
  24. Tsuchida, K. “Myostatin Inhibition by a Follistatin-Derived Peptide Ameliorates the Pathophysiology of Muscular Dystrophy Model Mice.” Acta Myologica : Myopathies and Cardiomyopathies : Official Journal of the Mediterranean Society of Myology, Pacini Editore SpA, July 2008, www.ncbi.nlm.nih.gov/pmc/articles/PMC2859604/. 
  25. Kanno Y;Ota R;Someya K;Kusakabe T;Kato K;Inouye Y; “Selective Androgen Receptor Modulator, YK11, Regulates Myogenic Differentiation of C2C12 Myoblasts by Follistatin Expression.” Biological & Pharmaceutical Bulletin, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/23995658/. 
  26. Kanno Y;Ota R;Someya K;Kusakabe T;Kato K;Inouye Y; “Selective Androgen Receptor Modulator, YK11, Regulates Myogenic Differentiation of C2C12 Myoblasts by Follistatin Expression.” Biological & Pharmaceutical Bulletin, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/23995658/. 
  27. Kearbey JD;Gao W;Narayanan R;Fisher SJ;Wu D;Miller DD;Dalton JT; “Selective Androgen Receptor Modulator (SARM) Treatment Prevents Bone Loss and Reduces Body Fat in Ovariectomized Rats.” Pharmaceutical Research, U.S. National Library of Medicine, pubmed.ncbi.nlm.nih.gov/17063395/. 
  28. Hatch, Orrin G. “S.2742 – 115th Congress (2017-2018): SARMs Control Act of 2018.” Congress.gov, 24 Apr. 2018, www.congress.gov/bill/115th-congress/senate-bill/2742. 
  29. “What Is Prohibited.” World Anti-Doping Agency, www.wada-ama.org/en/content/what-is-prohibited/search/Sarms. 
  30. Commissioner, Office of the. “FDA In Brief: FDA Warns against Using SARMs in Body-Building Products.” U.S. Food and Drug Administration, FDA, www.fda.gov/news-events/fda-brief/fda-brief-fda-warns-against-using-sarms-body-building-products. 
  31. Starr, Ranjani R. “Too Little, Too Late: Ineffective Regulation of Dietary Supplements in the United States.” American Journal of Public Health, American Public Health Association, Mar. 2015, www.ncbi.nlm.nih.gov/pmc/articles/PMC4330859/.

← Older Post Newer Post →